z-logo
Premium
Effect of Statin Treatment on Plasma 4β‐Hydroxycholesterol Concentrations
Author(s) -
BjörkhemBergman Linda,
Nylén Hanna,
Eriksson Mats,
Parini Paolo,
Diczfalusy Ulf
Publication year - 2016
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12537
Subject(s) - fluvastatin , atorvastatin , placebo , medicine , oxysterol , cholesterol , statin , endocrinology , hmg coa reductase , pharmacology , cytochrome p450 , endogeny , chemistry , metabolism , enzyme , reductase , biochemistry , alternative medicine , pathology , simvastatin
The endogenous oxysterol 4β‐hydroxycholesterol may be used as a marker for the drug‐metabolizing enzymes cytochrome P450 3A ( CYP 3A). The primary aim of this study was to investigate the effect of statin treatment on plasma 4β‐hydroxycholesterol concentrations. Plasma samples from a previously performed clinical study where gallstone patients had been treated with placebo (n = 6), 20 mg fluvastatin (n = 9) or 80 mg atorvastatin (n = 9) daily for 4 weeks were analysed. Hepatic CYP 3A mRNA levels had previously been shown to be unchanged in all three treatment groups. Plasma 4β‐hydroxycholesterol did not change significantly ( p = 0.92) in the placebo group, but treatment with low‐dose fluvastatin or high‐dose atorvastatin resulted in reductions in plasma concentration of 10.7% ( p < 0.05) and 36.5% ( p < 0.01), respectively. However, the 4β‐hydroxycholesterol/cholesterol ratio did not change significantly for the patients receiving placebo or patients receiving low‐dose fluvastatin. The ratio for patients receiving high‐dose atorvastatin increased by 12% ( p < 0.05). In conclusion, the total plasma cholesterol level is an important determinant for the plasma 4β‐hydroxycholesterol level.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here